Salestools LogoSalestools
Salestools AI Agents
Solutions
Resources
Company
Pricing
Salestools Logo

Salestools

The #1 AI Agent for Sales teams and Go To Market teams. Sell more, faster, with less effort.

Product

  • AI Sales Agents
  • Intent Data
  • Technology Data
  • Visitor Tracking
  • Co-Pilot
  • Social Selling

Solutions

  • Customer Service
  • E-commerce
  • SaaS
  • Enterprise
  • Small Business

Resources

  • The Report
  • Documentation
  • API Reference
  • Help Center
  • Blog
  • Case Studies
  • Webinars

Company

  • About
  • Careers
  • Press
  • Contact
  • Partners

Our locations

  • New York, HQ
  • Bucharest, AI Research Lab
  • Zug, Switzerland

Β© 2026 Salestools. All rights reserved.

Data Terms & SecurityPrivacy PolicyTerms of ServiceAcceptable Use
All systems operational
Salestools LogoSalestools
Salestools AI Agents
Solutions
Resources
Company
Pricing
Back to Reports
Fundraising

Walgreens Boots Alliance

Walgreens Boots Alliance Raises $40B in Public

108 Wilmot Road, Deerfield, IL 60015January 1, 20242 min read
Employees
315000+

Walgreens Boots Alliance Raises $40B in Public


Walgreens Boots Alliance has successfully raised $40B in a Public at a $50B valuation led by Public.


Company Overview


Walgreens Boots Alliance is a Healthcare company headquartered in 108 Wilmot Road, Deerfield, IL 60015, founded in 1901 with 315000+ employees.


Pharmacy and healthcare company


Fundraising Details


  • Amount Raised: $40B
  • Round Type: Public
  • Valuation: $50B
  • Date: 2024-01-01
  • Investors: Public

About Walgreens Boots Alliance


Pharmacy and healthcare company The company is positioned in the Healthcare sector, serving a growing market with innovative solutions.


Key Information


  • Headquarters: 108 Wilmot Road, Deerfield, IL 60015
  • Founded: 1901
  • Team Size: 315000+
  • Industry: Healthcare

What This Means


This funding round demonstrates strong investor confidence in Walgreens Boots Alliance's vision and execution. The capital will likely be used to:


  • Scale Operations: Expand the team and operational capacity
  • Product Development: Enhance existing products and develop new features
  • Market Expansion: Enter new markets and strengthen presence in existing ones
  • Technology Investment: Invest in infrastructure and technology capabilities

Industry Context


The Healthcare sector continues to attract significant investment as companies innovate to meet evolving market demands. Walgreens Boots Alliance's successful fundraising reflects the strong fundamentals and growth potential in this space.


Valuation Milestone


Reaching a $50B valuation marks an important milestone for Walgreens Boots Alliance, positioning the company among notable players in the Healthcare industry.


Looking Ahead


With this new capital, Walgreens Boots Alliance is well-positioned to execute on its growth strategy and continue building innovative solutions in the Healthcare space. The company's trajectory will be one to watch as it deploys this funding to achieve its next phase of growth.


This fundraising news was reported on 2024-01-01. For more information about Walgreens Boots Alliance, visit their headquarters at 108 Wilmot Road, Deerfield, IL 60015.

Company Info

Headquarters
108 Wilmot Road, Deerfield, IL 60015
Founded
1901
Team Size
315000+

Topics

Fundraising(2912)Public(771)HealthcareWalgreens Boots Alliance

Share

Related Reports

Fundraising
Tebra

Tebra Raises $250M Growth Financing | Healthcare Practice Management Platform

Healthcare practice management platform Tebra secures $250 million in growth financing led by Hildred Capital for AI-driven automation.

SalesTools Research
SalesTools Research
Jan 12, 2026
0 min readβ€’$250M
Fundraising
Harmattan AI

Harmattan AI Raises $200M Series B | Defense Tech Unicorn at $1.4B Valuation

French defense tech company Harmattan AI secures $200 million Series B led by Dassault Aviation, reaching unicorn status.

SalesTools Research
SalesTools Research
Jan 11, 2026
0 min readβ€’$200M
Fundraising
AirNexis Therapeutics

AirNexis Therapeutics Raises $200M Series A | Novel COPD Treatment

Biotech AirNexis Therapeutics emerges from stealth with $200 million Series A for dual PDE3/4 inhibitor COPD therapy.

SalesTools Research
SalesTools Research
Jan 11, 2026
0 min readβ€’$200M

Turn your sales ideas into reality today

Start your 14-day Pro trial today. No credit card required.

Start building for free